Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

WORCESTER, Massachusetts, July 08, 2007 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE

Venous thromboembolism (VTE) risk is high among hospital patients and most of these at-risk patients are not protected with adequate prophylaxis according to data from the international ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study presented today at the XXIst International Society on Thrombosis and Haemostasis (ISTH) congress in Geneva.

VTE is a preventable disease which contributes significantly to morbidity and mortality among patients hospitalized for acute medical and surgical illnesses. Many complications and deaths due to VTE could be prevented using thromboprophylaxis as recommended by evidence based guidelines, but some studies have shown that there is a gap between evidence and practice in the hospital setting. Lack of awareness and uncertainty about the prevalence of patients at risk for VTE are among the major reasons accounting for this gap (1, 2). To date, there has been no large international study performed in hospitals selected at random around the world to evaluate VTE risk and prophylaxis practice globally.

ENDORSE collected data on more than 60,000 patients who were surveyed across 358 acute care hospitals randomly selected in 32 countries, encompassing 5 continents. All participating hospitals followed the same standard multinational protocol to survey the patients present in the wards.

The main objectives of ENDORSE were to assess the prevalence of VTE risk in the acute hospital care setting and to determine the proportion of at-risk patients who receive recommended prophylaxis using the d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
(Date:9/15/2014)... 15, 2014 Biomerics LLC, a leading ... market, announced its merger with Access Point Technologies ... new division was formed to provide next generation ... the structure heart, interventional radiology, interventional cardiology, and ... Catheter will be led by Steve Berhow ...
(Date:9/15/2014)... 15, 2014  MedExpress Urgent Care, a national leader in ... flu shots for ages four and up at each of ... get their flu shot early. According to ... of June, making late summer and early fall an ideal ... Vice President of Provider and Clinical Quality, Thomas Pangburn ...
Breaking Medicine Technology:The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2MedExpress Quotes Late Summer, Early Fall As Best Time to Receive Flu Shot 2
... March 1, 2011 Heska Corporation (Nasdaq: ... and specialty products to veterinarians, today announced the addition ... in-clinic blood analyzers. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ... analyzer is used to measure lactate, and is ideal ...
... successful contract packaging and re-packaging companies in the ... new, single-source industry leader called Aphena Pharma ... corporation based on a strategic alliance between Celeste ... Packaging; all long-term specialized leaders in the contract ...
Cached Medicine Technology:Heska Introduces New Lactate Meter Analyzer 2Merger of Four Pharmaceutical Companies Announced 2
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... approximately one out of every 40 individuals in the United ... muscular atrophy (SMA), a neurodegenerative disease that causes muscles to ... have made a recent breakthrough with the development of a ... of the disease. In April, a patent was filed for ... lab is using to fight SMA is to ,repress the ...
(Date:9/15/2014)... Worth, FL (PRWEB) September 15, 2014 ... policy away from putting low-level offenders in jail and ... Treatment Group sees this shift as a positive change. ... of prescription drug and heroin abuse. According to an ... both parties are calling for a shift away from ...
(Date:9/15/2014)... September 15, 2014 Florida is now one ... anyone who refuses a breath test could be forced to ... the new policy will prevent more people from drinking and ... among the highest rate of breathalyzer refusal. The new law ... According to CBS Miami , the new Florida law ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:White House Shifts Policy on Drugs 2Health News:New DUI Law Makes Blood Tests Mandatory 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... DIEGO, Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: ... an investigational new,drug (IND) application to the U.S. ... an internally developed, orally-bioavailable, small,molecule inhibitor of the ... Phase I clinical trials of SGX523 for solid ...
... Germany and OXFORD, England, December 3 /PRNewswire-FirstCall/,-- Evotec ... it has,completed the sale of its Chemical Development ... GBP 31.5 million (approx. EUR 44 million),effective November ... focus even more on its strategy to,become an ...
... donation" appeal at last,night,s Hutch Holiday Gala helped push ... Fred Hutchinson Cancer Research Center., The annual black-tie ... event took place from 5 p.m. until midnight at ... portion of the live auction during which every,dollar donated ...
... at bay, expert says , SUNDAY, Dec. 2 (HealthDay News) -- ... all too easy to pack on extra pounds when joining family ... help you avoid weight gain, says Jennifer Ebelhar, an assistant professor ... to indulge in a little of your favorite holiday treats. But ...
... hours, work at night, struggle to remain awake at work, ... drowsy driving episode, according to a study published in the ... authored by Linda D. Scott, PhD, of Grand Valley State ... collected from 895 full-time hospital staff nurses, who completed logbooks ...
... 1 issue of the journal SLEEP is the first to ... duration are associated with an elevated risk of mortality by ... Jane E. Ferrie, PhD, of the University College London Medical ... and 55 years of age. Baseline screening (Phase 1), ...
Cached Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 2Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 3Health News:Evotec Completes Divesture of Chemical Development Business to Aptuit 4Health News:32nd Annual Hutch Holiday Gala Raises Millions for Cancer Research 2Health News:32nd Annual Hutch Holiday Gala Raises Millions for Cancer Research 3Health News:Holidays Don't Have to Leave You Heavier 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4Health News:Short, long sleep duration associated with increased mortality 2
... unique system uses prolene as thread-guide reducing ... The hollow Ritleng Probe is inserted into ... thread-guide is fed through it. The probe ... to pull the silicone tubing in place. ...
... For canalicular laceration or imperforate ... and Stainless Steel Probe. Box ... securely swaged into malleable stainless ... by punctum plug: no knots, ...
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
Medicine Products: